Board Update
13 November 2026
Molecule Group plc
(the "Company", "Group" or "Molecule")
Board Update
Molecule Group plc, the Company building a leading regulated UK ePharmacy through buy-and-build, is pleased to announce the appointment of Andrew Houghton as an independent Non-Executive Director with immediate effect.
Mr Houghton brings considerable commercial, consumer-brand and digital experience, having previously held senior roles at Nike Inc from July 2012 to May 2024 and at Unilever PLC, where he established a new business unit to develop the Unilever UK eCommerce strategy. Prior to this, Mr Houghton spent 8 years at Accenture in the management consulting practice. Mr Houghton currently serves as Managing Director of Lands’ End Europe Limited, the European subsidiary of Lands’ End Corporation, a leading online clothing retailer.
The Company also announces that Dr David Wong, Non-Executive Director, steps down from the board of directors (the “Board”) with immediate effect. The Board would like to thank David for his contribution to the Company and wishes him well for the future.
Susan Clement Davies, Chair of Molecule, commented: “We are delighted to welcome Andrew to Molecule. His considerable commercial, consumer-brand and digital experience will be invaluable as we grow the business and progress our buy-and-build strategy.”
Andrew John Houghton, aged 50, is currently a director of Lands’ End Europe Limited. Andrew has held no other directorships/partnerships in the past five years.
Save as set out above, there is no further information to be disclosed in relation to Andrew Houghton’s appointment to the Board pursuant to AIM Rule 17 or paragraph (g) of Schedule Two of the AIM Rules for Companies.
- Ends -
For further information please contact:
|
Molecule Group plc Michael Kraftman, Chief Executive Officer Keith Butcher, Chief Financial Officer Brendan O’Brien, Chief Operating Officer |
|
|
Canaccord Genuity Limited
Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott |
Tel: +44 (0) 20 7523 8000 |
|
Alma Strategic Communications Justine James / Josh Royston / Sam Modlin / Will Merison |
Tel: +44 (0)20 3405 0205 |
Notes to Editors
Molecule Group plc (AIM: MOL) is building a leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.
The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise. For more information, visit investors.molecule.co.uk.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE